Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.52 +2.69 (+5.19%)
Streaming Delayed Price Updated: 12:28 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,869,206
Open 54.60
Bid (Size) 54.52 (2)
Ask (Size) 54.53 (4)
Prev. Close 51.83
Today's Range 54.02 - 54.99
52wk Range 45.05 - 139.74
Shares Outstanding N/A
Dividend Yield 4.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows
Novo Nordisk is showing signs that a comeback might be on the horizon after it hit the lows of its 52-week trading range. 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga

Performance

YTD
-37.7%
-37.7%
1 Month
-15.2%
-15.2%
3 Month
-18.7%
-18.7%
6 Month
-33.8%
-33.8%
1 Year
-59.7%
-59.7%

More News

Read More
Market Movers: UnitedHealth, Intel, and Novo Nordisk Among Top Performers Reshaping the Financial Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today
Via Stocktwits
Why Novo Nordisk Stock Popped Monday
Via The Motley Fool
Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients
Via Stocktwits
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
Via Investor's Business Daily
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
Dow Futures Decline After Recent Rally, All Eyes On Powell’s Jackson Hole Speech: NVO, UNH, FSLR, RUN, PANW Among Stocks To Watch
Via Stocktwits
Topics Stocks
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
1 Stock Down 40% This Year to Buy and Hold
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Via The Motley Fool
Topics Economy
Why Novo Nordisk Flew Almost 3% Higher on Friday
Via The Motley Fool
Topics Government
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Via Benzinga
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Via Benzinga
This House of Representative Just Bought Up To $95K In Novo Nordisk Stock
Via Benzinga
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Via Benzinga
Topics Artificial Intelligence
Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 54.52
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/18/25 12:28 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.